Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday July 29, 1997 - 8:29 AM EDT
The L.E.A.P.S. synthetic vaccine technology is intended to selectively stimulate the immune system to more effectively fight bacterial, viral and parasitic infections as well as cancer and autoimmune diseases, when it cannot do so on its own. Early targets of the Company's research are AIDS, herpes simplex, malaria and tuberculosis.
Preventive vaccines in use today consist of either killed or disabled microbes, or "subunit" vaccines containing whole proteins isolated from infectious organisms or recombinant sources. These types of vaccines stimulate protective antibody responses, but are complex to make and sometimes have side effects that limit their use. Synthetic peptide heteroconjugates which use two or more chemically-synthesized peptides linked together, are designed to bind to one or more specific sets or subsets of T-cells. They offer advantages over subunit or killed microbe vaccines in that they are well-defined chemical entities which are easy to manufacture and characterize, and they present no pathogen contamination concerns.
While synthetic vaccines offer many potential advantages, their use has been limited by their inability to elicit appropriate immune responses. Linking the antigens to immunogenic carrier proteins or making large, cross- linked peptide constructs can increase the immunogenicity of a synthetic antigen. However, these approaches present other problems, including manufacturing difficulties and loss of effectiveness associated with repeated use of the same carrier. L.E.A.P.S. constructs effectively induce a specific long-lived defined IgG isotype antibody response, with little to no immune response to the L.E.A.P.S. ligand itself.
Geert Kersten, Chief Executive Officer of CEL-SCI Corporation, says, "In September we will present data on herpes simplex animal challenge studies using the L.E.A.P.S. heteroconjugate technology. We believe that L.E.A.P.S. has the potential to become the basis for a number of vaccines and treatments."
CEL-SCI Corporation is a pioneer in the field of natural immunotherapy. The Company is developing immune based treatments for cancer, AIDS, tuberculosis, malaria and herpes simplex.
When used in this report, the words "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinic results demonstrated in preclinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 1996. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
SOURCE: CEL-SCI Corporation
Contact: Geert Kersten, Chief Executive Officer of CEL-SCI, 703-549-5293
Copyright (c) 1997/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
970729
PR970722
Copyright © 1997 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .